ICD-10: C83.96

Non-follicular (diffuse) lymphoma, unspecified, particularly affecting the intrapelvic lymph nodes, is classified under ICD-10 code C83.96. This type of lymphoma is a form of non-Hodgkin lymphoma (NHL) characterized by the diffuse infiltration of lymphoid tissue, which can lead to various clinical presentations and symptoms. Below is a detailed overview of the clinical presentation, signs, symptoms, and patient characteristics associated with this condition.

Clinical Presentation

Overview of Non-Follicular Lymphoma

Non-follicular lymphoma encompasses a range of aggressive lymphomas that do not exhibit the follicular pattern typical of some other lymphomas. The unspecified nature of C83.96 indicates that the specific subtype of diffuse lymphoma has not been determined, which can complicate diagnosis and treatment.

Common Symptoms

Patients with non-follicular lymphoma affecting the intrapelvic lymph nodes may present with a variety of symptoms, including:

• Lymphadenopathy: Swelling of lymph nodes, particularly in the pelvic region, which may be palpable during a physical examination.
• Abdominal Pain or Discomfort: Patients may experience pain due to the enlargement of lymph nodes or pressure on surrounding organs.
• B Symptoms: These include systemic symptoms such as:
• Fever: Often low-grade but can be persistent.
• Night Sweats: Profuse sweating during the night that can disrupt sleep.
• Weight Loss: Unintentional weight loss over a short period, often exceeding 10% of body weight.
• Fatigue: A common complaint among patients, often due to the body's response to cancer.
• Anemia: Patients may present with signs of anemia, such as pallor or fatigue, due to bone marrow involvement or chronic disease.

Additional Symptoms

Depending on the extent of the disease and its impact on surrounding structures, patients may also experience:

• Gastrointestinal Symptoms: Such as nausea, vomiting, or changes in bowel habits if lymph nodes are compressing the intestines.
• Urinary Symptoms: Including frequency or urgency if lymph nodes are affecting the bladder or ureters.
• Neurological Symptoms: Rarely, if there is central nervous system involvement, patients may experience headaches, seizures, or other neurological deficits.

Patient Characteristics

Demographics

• Age: Non-follicular lymphomas can occur in adults of any age but are more common in older adults, typically those over 60 years.
• Gender: There is a slight male predominance in the incidence of non-Hodgkin lymphomas, including non-follicular types.

Risk Factors

Several risk factors may predispose individuals to develop non-follicular lymphoma, including:

• Immunosuppression: Patients with compromised immune systems, such as those with HIV/AIDS or those on immunosuppressive therapy, are at higher risk.
• Autoimmune Diseases: Conditions like rheumatoid arthritis or Sjögren's syndrome may increase the risk of developing lymphomas.
• Exposure to Chemicals: Certain chemicals, such as pesticides or solvents, have been linked to an increased risk of lymphoma.
• Family History: A family history of lymphoma or other hematological malignancies may also be a contributing factor.

Diagnostic Considerations

Diagnosis typically involves a combination of imaging studies (such as CT scans) to assess lymph node involvement and biopsy of affected lymph nodes to confirm the histological type of lymphoma. Laboratory tests may also be conducted to evaluate blood counts and assess for anemia or other abnormalities.

Conclusion

Non-follicular (diffuse) lymphoma, unspecified, affecting the intrapelvic lymph nodes, presents with a range of symptoms primarily related to lymphadenopathy and systemic effects. Understanding the clinical presentation and patient characteristics is crucial for timely diagnosis and management. If you suspect lymphoma based on these symptoms, it is essential to seek further evaluation from a healthcare professional for appropriate diagnostic testing and treatment options.

ICD-10 code C83.96 refers to Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes. This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses a diverse group of blood cancers that originate in the lymphatic system. Below is a detailed clinical description and relevant information regarding this specific code.

Clinical Description

Definition of Non-follicular Lymphoma

Non-follicular lymphoma is characterized by the proliferation of lymphoid tissue that does not exhibit the follicular architecture typical of follicular lymphoma. This type of lymphoma is often aggressive and can manifest in various forms, including diffuse large B-cell lymphoma (DLBCL), which is the most common subtype of non-Hodgkin lymphoma. The term "diffuse" indicates that the lymphoma cells are spread throughout the lymphatic tissue rather than being localized in discrete nodules.

Involvement of Intrapelvic Lymph Nodes

The designation of "intrapelvic lymph nodes" indicates that the lymphoma has specifically affected the lymph nodes located within the pelvic cavity. These nodes are crucial for filtering lymphatic fluid and are involved in immune responses. The involvement of intrapelvic lymph nodes can lead to various symptoms, including:

• Abdominal pain or discomfort: Due to lymph node enlargement.
• Swelling: In the pelvic region, which may be noticeable during physical examination.
• Systemic symptoms: Such as fever, night sweats, and unexplained weight loss, which are common in lymphoproliferative disorders.

Diagnosis and Staging

Diagnosis typically involves a combination of imaging studies (such as CT scans or PET scans) and biopsy of the affected lymph nodes. The staging of non-follicular lymphoma is crucial for determining the appropriate treatment plan and prognosis. The Ann Arbor staging system is commonly used, which classifies the disease based on the number of lymph node regions involved and the presence of systemic symptoms.

Treatment Options

Treatment for non-follicular lymphoma, particularly when it involves intrapelvic lymph nodes, may include:

• Chemotherapy: Often the first line of treatment, especially for aggressive forms like DLBCL.
• Radiation therapy: May be used in conjunction with chemotherapy or as a standalone treatment for localized disease.
• Targeted therapies: Such as monoclonal antibodies (e.g., rituximab) that specifically target lymphoma cells.
• Stem cell transplant: Considered in cases of relapsed or refractory disease.

Prognosis

The prognosis for patients with non-follicular lymphoma can vary widely based on several factors, including the specific subtype, the stage at diagnosis, the patient's overall health, and response to treatment. Generally, aggressive forms of non-follicular lymphoma may have a poorer prognosis compared to indolent forms, but advancements in treatment have improved outcomes significantly.

Conclusion

ICD-10 code C83.96 captures a specific and clinically significant condition within the spectrum of non-Hodgkin lymphoma. Understanding the characteristics, symptoms, and treatment options for non-follicular lymphoma, particularly when it involves intrapelvic lymph nodes, is essential for healthcare providers in managing this complex disease effectively. Early diagnosis and appropriate treatment are critical for improving patient outcomes in this challenging area of oncology.

ICD-10 code C83.96 refers to "Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes." This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses various types of lymphomas that do not originate from follicular (B-cell) structures. Below are alternative names and related terms associated with this specific code.

Alternative Names for C83.96

1. Diffuse Large B-Cell Lymphoma (DLBCL): While DLBCL is a specific subtype of non-follicular lymphoma, it is often included in discussions about diffuse lymphomas due to its aggressive nature and prevalence.

2. Non-Hodgkin Lymphoma (NHL): This is a broader term that includes all types of lymphomas that are not classified as Hodgkin lymphoma. C83.96 is a specific instance within this category.

3. Lymphoma, Non-follicular Type: This term emphasizes the non-follicular nature of the lymphoma, distinguishing it from follicular lymphomas.

4. Unspecified Non-follicular Lymphoma: This term highlights the unspecified aspect of the diagnosis, indicating that the exact subtype of non-follicular lymphoma has not been determined.

Related Terms

1. Lymphadenopathy: This term refers to the enlargement of lymph nodes, which is a common symptom in various types of lymphoma, including non-follicular lymphomas.

2. Lymphoma Staging: The process of determining the extent of lymphoma spread, which is crucial for treatment planning. Staging can involve the assessment of intrapelvic lymph nodes.

3. Hematologic Malignancies: A broader category that includes all cancers of the blood, bone marrow, and lymphatic system, including non-follicular lymphomas.

4. Intraperitoneal Lymphoma: While not a direct synonym, this term may be used in clinical contexts to describe lymphomas that affect lymph nodes within the abdominal cavity, which can include intrapelvic nodes.

5. B-cell Lymphoma: Since many non-follicular lymphomas are of B-cell origin, this term is often used in conjunction with discussions about non-follicular types.

6. Stage IV Lymphoma: If the lymphoma has spread to distant lymph nodes, including those in the pelvis, it may be classified as Stage IV, which is relevant for treatment and prognosis.

Conclusion

Understanding the alternative names and related terms for ICD-10 code C83.96 is essential for accurate diagnosis, treatment planning, and communication among healthcare professionals. These terms help clarify the nature of the lymphoma and its implications for patient care. If you need further information or specific details about treatment options or prognosis related to this condition, feel free to ask!

The diagnosis of Non-follicular (diffuse) lymphoma, unspecified, particularly in the context of intrapelvic lymph nodes, is guided by a combination of clinical evaluation, imaging studies, histopathological examination, and specific diagnostic criteria. Below is a detailed overview of the criteria and processes involved in diagnosing this condition, which corresponds to the ICD-10 code C83.96.

Overview of Non-follicular Lymphoma

Non-follicular lymphoma, often referred to as diffuse large B-cell lymphoma (DLBCL), is a type of non-Hodgkin lymphoma characterized by the rapid proliferation of malignant B-cells. The term "unspecified" indicates that the specific subtype of lymphoma has not been determined, which can occur in various clinical scenarios.

Diagnostic Criteria

1. Clinical Evaluation

• Symptoms: Patients may present with nonspecific symptoms such as fever, night sweats, weight loss, and fatigue, often referred to as "B symptoms." Localized symptoms may arise from lymphadenopathy or organ involvement, particularly in the pelvic region.
• Physical Examination: A thorough physical examination may reveal enlarged lymph nodes, particularly in the cervical, axillary, or inguinal regions, and abdominal or pelvic masses.

2. Imaging Studies

• CT Scans: Computed tomography (CT) scans of the abdomen and pelvis are crucial for identifying enlarged lymph nodes and assessing the extent of disease. In cases of intrapelvic lymph nodes, CT can help visualize lymphadenopathy and any associated masses.
• PET Scans: Positron emission tomography (PET) scans may be utilized to evaluate metabolic activity in lymph nodes and to assess for potential sites of disease spread.

3. Histopathological Examination

• Biopsy: A definitive diagnosis requires a biopsy of the affected lymph node or mass. This can be performed via excisional biopsy, core needle biopsy, or fine-needle aspiration (FNA).
• Pathological Analysis: The biopsy specimen is examined microscopically to identify the presence of atypical lymphoid cells. Immunohistochemistry is often employed to determine the cell type and to differentiate between various subtypes of lymphoma. Markers such as CD20, CD10, and BCL-6 are commonly assessed.

4. Laboratory Tests

• Blood Tests: Complete blood counts (CBC) and other laboratory tests may be performed to assess overall health and to check for anemia or other abnormalities that may suggest lymphoma.
• Bone Marrow Biopsy: In some cases, a bone marrow biopsy may be necessary to evaluate for bone marrow involvement, which can influence staging and treatment decisions.

5. Staging

• Ann Arbor Staging System: The staging of lymphoma is critical for treatment planning. The Ann Arbor system classifies lymphoma based on the number of lymph node regions involved and whether the disease has spread to extranodal sites. In the case of intrapelvic lymph nodes, the involvement of the abdomen and pelvis is particularly relevant.

Conclusion

The diagnosis of Non-follicular (diffuse) lymphoma, unspecified, particularly involving intrapelvic lymph nodes (ICD-10 code C83.96), relies on a comprehensive approach that includes clinical assessment, imaging studies, histopathological evaluation, and laboratory tests. Accurate diagnosis is essential for determining the appropriate treatment strategy and improving patient outcomes. If you have further questions or need more specific information regarding treatment options or management strategies, feel free to ask!

Non-follicular (diffuse) lymphoma, classified under ICD-10 code C83.96, refers to a type of non-Hodgkin lymphoma (NHL) that is characterized by the diffuse infiltration of lymphoid tissue, often leading to aggressive disease progression. This specific code indicates that the lymphoma is located in the intrapelvic lymph nodes but does not specify the exact subtype of diffuse lymphoma. Here, we will explore the standard treatment approaches for this condition, including chemotherapy, radiation therapy, and emerging therapies.

Overview of Non-Follicular Lymphoma

Non-follicular lymphomas encompass a variety of aggressive lymphomas, including diffuse large B-cell lymphoma (DLBCL) and other subtypes. These lymphomas are typically characterized by rapid growth and may present with symptoms such as lymphadenopathy, fever, night sweats, and weight loss. The treatment approach often depends on the specific subtype, stage of the disease, and the patient's overall health.

Standard Treatment Approaches

1. Chemotherapy

Chemotherapy remains the cornerstone of treatment for non-follicular lymphomas. The most commonly used regimen for aggressive lymphomas, including DLBCL, is the R-CHOP regimen, which consists of:

• Rituximab: A monoclonal antibody targeting CD20 on B-cells.
• Cyclophosphamide: An alkylating agent.
• Doxorubicin (Adriamycin): An anthracycline antibiotic.
• Vincristine (Oncovin): A vinca alkaloid.
• Prednisone: A corticosteroid.

This combination is typically administered in cycles over several months, with the exact number of cycles depending on the response to treatment and the specific clinical scenario[1][2].

2. Radiation Therapy

Radiation therapy may be utilized in conjunction with chemotherapy, particularly in localized cases or when there is a significant mass effect from the lymphoma. It can be effective in reducing tumor burden and alleviating symptoms. In some cases, involved-field radiation therapy (IFRT) is used to target only the areas affected by lymphoma, minimizing exposure to surrounding healthy tissues[3].

3. Stem Cell Transplantation

For patients with relapsed or refractory non-follicular lymphoma, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be considered. This approach allows for the administration of higher doses of chemotherapy than would be tolerated alone, with the goal of eradicating the disease and restoring bone marrow function[4].

4. Targeted Therapies and Immunotherapy

Recent advancements in the treatment of non-follicular lymphomas have introduced targeted therapies and immunotherapies. These include:

• Brentuximab vedotin: An antibody-drug conjugate used for certain types of lymphomas.
• CAR T-cell therapy: A form of immunotherapy that modifies a patient’s T-cells to better recognize and attack lymphoma cells. This is particularly relevant for patients with relapsed or refractory disease[5].

5. Clinical Trials

Patients with non-follicular lymphoma may also be eligible for clinical trials exploring new treatment options, including novel agents and combination therapies. Participation in clinical trials can provide access to cutting-edge therapies that may improve outcomes[6].

Conclusion

The treatment of non-follicular lymphoma, particularly in the context of intrapelvic lymph nodes, involves a multidisciplinary approach that includes chemotherapy, radiation therapy, and potentially stem cell transplantation or targeted therapies. The choice of treatment is tailored to the individual patient based on the specific characteristics of the lymphoma, the stage of the disease, and the patient's overall health. Ongoing research and clinical trials continue to evolve the landscape of treatment options, offering hope for improved outcomes in this challenging disease.

For patients diagnosed with C83.96, it is crucial to work closely with a healthcare team specializing in hematology and oncology to determine the most appropriate treatment plan.